Authors
Latest:
Dr. Bordoni on the Utility of Adjuvant Atezolizumab in the Adjuvant Setting in NSCLCRodolfo Bordoni, MD, discusses the utility of atezolizumab in the adjuvant setting in non–small cell lung cancer.
Latest:
Dr. Schenk on the Effect of Nivolumab Plus Relatlimab in Basal Cell CarcinomaKara M. Schenk, MD, discusses the effect of nivolumab plus relatlimab in advanced basal cell carcinoma.
Latest:
Advice for Community Physicians Treating Patients with Neuroendocrine Tumor-Associated Carcinoid SyndromeDrs Das, Pommier, and Zacks share their advice for community physicians treating patients who have neuroendocrine tumors with carcinoid syndrome and carcinoid heart disease.
Latest:
Dr. Friedland on a Multimodal Screening Blood Test to Detect CRCShai Friedland, MD, discusses a multimodal screening blood test for advanced adenomas in colorectal cancer.
Latest:
Preparing and Delivering a Virtual Learning SessionStrategies are important to optimize learning in the virtual environment including speaker preparation, creating a virtual learning climate, and encouraging and enhancing interaction.
Latest:
Advice for New Nurse Practitioners Working With Patients With Endometrial CancerClosing their discussion, the panel shares advice for new nurse practitioners caring for patients who have endometrial cancer.
Latest:
Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComaDr Wagner discusses unmet needs for patients with PEComa, ongoing research to address these gaps, and findings from the AMPECT trial.
Latest:
Dr Mathews on Maintenance Olaparib in Ovarian CancerCara A. Mathews, MD, discusses 7-year overall survival data from the phase 3 SOLO-1 trial in patients with ovarian cancer.
Latest:
Dr. Sridhar on the Long-Term Data from the JAVELIN Bladder 100 Trial in Advanced Urothelial CarcinomaSrikala Sridhar, MD, MSc, FRCPC, discusses long-term follow-up data from the phase 3 JAVELIN Bladder 100 in patients with advanced urothelial carcinoma.
Latest:
Current Treatment Options for Patients with Steroid-Refractory Acute GVHDClosing her discussion, Dr Pashna Munshi reviews recent data on the available treatment options for patients with steroid-refractory acute GVHD.
Latest:
Dr. Anne on the Practice-Changing Data of DESTINY-Breast04 in HER2-Low Breast CancerMadhurima Anne, MD, discusses the practice-changing data of the phase 3 DESTINY-Breast04 trial in patients with HER2-low breast cancer.
Latest:
Trainees Deserve Better FeedbackFeedback plays a key role in medical edu-cation and faculty development as it allows everyone to evaluate their performance and improve their intrapersonal skills.
Latest:
Dr Alvero on Antitumor Immunological Memory in Ovarian Cancer ModelsAyesha Alvero, MD, MSc, discusses findings from a preclinical study investigating the antitumor effects and recurrence prevention abilities of a virus-like vesicle thought to establish immunological memory in mouse models with ovarian cancer.
Latest:
Ongoing Research on MRD Detection May Shift Outcomes for Posttransplant AMLThe prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.
Latest:
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast CancerCapivasertib plus fulvestrant improved time to second progression in patients with pretreated HR-positive, HER2-negative advanced breast cancer.
Latest:
The US Oncology Network Extends Its Reach into Tennessee with The Addition of Nashville Oncology AssociatesThe Network continues its strong growth trajectory and its mission to enhance community-based cancer care.
Latest:
Dr Moustafa on the Evolving Use of Bispecific Antibodies in DLBCLMuhamad Alhaj Moustafa, MD, MS, discusses the evolution of bispecific antibodies in diffuse large B-cell lymphoma.
Latest:
Dr Stokes on Radiation Vs Surgery in HPV+ OPSCCWilliam (Bill) Stokes, MD, discusses the use of radiation vs surgery for the treatment of patients with human papillomavirus–related oropharyngeal squamous cell carcinoma.
Latest:
Dr. Wee on the Current Landscape of Nonmetastatic CRPC Treatment and ClassificationChristopher Wee, MD discusses the current treatment landscape for nonmetastatic castration-resistant prostate cancer, and how the success of new diagnostic tools decreases the need for this classification.
Latest:
Final Thoughts on New Developments and Emerging AgentsPanelists conclude by reviewing possible advancements on the horizon in AML such as the potential emergence of Menin inhibitors and bispecific T-cell engagers as well as improved methods for predicting response and preventing relapse.
Latest:
Dr. DiSilvestro on the Long-Term OS Benefit of Olaparib Maintenance in Ovarian CancerPaul A. DiSilvestro, MD, discusses the long-term survival benefit of olaparib maintenance in advanced BRCA-mutated ovarian cancer.
Latest:
Dr Liu on Surgical Outcomes Following Radiation and Chemotherapy in Rectal CancerI-Chia (Daniel) Liu, MD, discusses surgical and local control outcomes following short-course radiation therapy and chemotherapy for rectal cancer.
Latest:
Dr. Bander on Preliminary Data on 225Ac-J591 Plus Pembrolizumab in mCRPCNeil H. Bander, MD, discusses preliminary results from a phase 1/2 study of pembrolizumab in combination with an androgen-receptor signaling inhibitor and alpha-PSMA-targeted radionuclide therapy in mCRPC.
Latest:
Dr. Visvanathan on the Rationale for Evaluating Lipophilic Statins in Epithelial Ovarian CancerKala Visvanathan, MD, MBBS, MHS, discusses the rationale for evaluating lipophilic statins in epithelial ovarian cancer.
